Companies › SK Life Science
3 active drug programs in 4 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 4; Neurology, Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cenobamate (YKP3089) GABA-A receptor; anion channel positive allosteric modulator; Sodium channel alpha subunit inhibitor | GABRA1, GABRB2, GABRG2, GABRB3, GABRA4 | Phase 4 | Focal Onset Seizure; Partial Epilepsy | May 2027 |
| Carisbamate GABA transporter 1 (GAT-1) inhibitor | SLC6A4 | Phase 3 | Seizures | Feb 2027 |
| SKL35501 NTSR1-targeting small molecule linked to alpha emitter 225Ac | NTSR1 | Phase 1 | Selected Advanced Solid Tumors | Jul 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05067634 | Cenobamate (YKP3089) | Phase 3 | Partial Epilepsy | Neurology | Oct 2026 |
| NCT05219617 | Carisbamate | Phase 3 | Seizures | Neurology | Feb 2027 |
| NCT06453213 | Cenobamate (YKP3089) | Phase 4 | Focal Onset Seizure | Neurology | May 2027 |
| NCT07812805 | SKL35501 | Phase 1 | Selected Advanced Solid Tumors | Oncology | Jul 2030 |
Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group Acacia Pharma Sedana Medical Intra-Cellular Therapies Otsuka AlgoTherapeutix Takeda
AB Science Lipocine Pharmasoft Italfarmaco Suven Life Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.